Asset Type: Media article

Overview of PacBio User Group meeting discussing latest range of applications and growing user base

Researchers at the University of Maryland’s Institute for Genome Sciences have been awarded a $1.4 million research program contract by the US FDA to sequence, assemble, and annotate a population of bacterial pathogens and make that data available in public databases.

A review of literature where the authors customize a DNA sequencer to use as an instrument for single-molecule fluorescence detection.

Within the last ten years, a few dozen scientists have turned to genomics to understand why some weeds have developed herbicide resistance or become more invasive.

Long-read sequencing can enable researchers to not only detect what drug-resistance mutations are present in someone with HIV, but also whether those mutations are present in one strain or spread across multiple strains of the virus circulating in that patient.

The Department of Energy’s Joint Genome Institute is looking to establish itself as a complete genomics facility that offers state-of-the art technologies in experimental data generation and biological data interpretation as well as user interactions to help solve genomic science problems.

A look at the promise of genomic sequencing to carry out the tasks of discovering (and genotyping) chromosomal structural variations (CVs) and how recent developments and promised improvements may allow it ultimately to fulfill its promise.

A look back at the evolution of Pacific Biosciences since 2012 and current position in the marketplace.

PacBio CEO Mike Hunkapiller discusses the focus for the company in 2014 and why long reads are important in this Next-Generation Sequencing podcast series.

Pacific Biosciences is expanding its technology into the realms of transcriptome sequencing and human genome sequencing, the company and its customers demonstrated at the AGBT 2014 meeting.